A new publication involving secretin was released on October 5, 2026. The paper, titled "Intestinal FXR agonism synergizes with leptin to improve obesity by reducing appetite via secretin," appeared in EMBO reports.
The publication is indexed under PubMed ID 42834123. It is listed as a new addition to the scientific literature concerning secretin and its relationship to intestinal FXR agonism and leptin signaling, as described in the title.
This brief reports only that the publication exists, along with its title, journal, and date, as provided in the event record. No findings, outcomes, or conclusions from the study are described here beyond what is stated in the title itself. Readers interested in the specific results, methodology, or data presented in the paper should consult the full text directly through the journal or PubMed listing.
Secretin remains an approved compound. Readers can consult the compound overview for additional background and context on secretin.